Cambium Bio Limited
CMB
株式のランク
#32451
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
株価
$0.31613178
最終同期: 2026-10-21
時価総額
$9.30M
変化（1日）
-0.39%
変化（1年）
5,893.70%
国
AU
取引 Cambium Bio Limited (CMB)
カテゴリー
Healthcare
Cambium Bio Limited（CMB）の株価履歴
終値の最高値: $0.01 （2024-05-01）
終値の最安値: $0.25 （2013-09-01）
終値の最安値: $0.25 （2013-09-01）
Cambium Bio Limited の株価履歴（2013 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2024 | 119.50% |
| 2023 | -92.08% |
| 2022 | -41.49% |
| 2021 | -42.78% |
| 2020 | 56.83% |
| 2019 | -53.42% |
| 2018 | 31.72% |
| 2017 | -21.51% |
| 2016 | 74.18% |
| 2015 | -41.39% |
| 2014 | -67.54% |
| 2013 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
